Exploring therapeutic methods for C3 Glomerulopathy (C3G)
Rare Kidney Condition Called C3 Glomerulopathy (C3G) Has Limited Treatment Options, but New Therapies Are Emerging
Current treatments for C3G primarily aim to support kidney function and suppress the immune system, while emerging therapies seek to interrupt the proteins involved in the disease. This condition affects approximately 2 to 3 people per million and leads to protein buildup in the kidneys' filtering tissues, potentially causing kidney failure.
The immune system becomes overactive in C3G, due to changes in specific genes that regulate the body's complement system, a component of the immune system. When these genes change, the body produces an excess of C3 protein, which then forms deposits in the kidneys. The glomeruli — blood vessels in the kidneys responsible for filtering waste and excess fluid — bear the brunt of this damage, leading to progressive impairment in their function.
With no cure for C3G, treatment begins with strategies to maintain kidney health. Doctors often recommend systemic treatments to suppress the immune system. While genetics are believed to play a role in the development of C3G, it is not strictly inherited; most people with the condition carry antibodies that impair the regular function of the complement system.
A selection of medications is currently used to manage C3G. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) help lower blood pressure and limit protein leakage into the urine. MMF and glucocorticoids, both immune-suppressing drugs, may be recommended once a person has had declining kidney function for at least six months or shows signs of condition progression, such as increasing levels of protein in the urine.
Complement inhibitors are also used to slow kidney damage caused by C3G. These medications stop activity in the complement system and may be suggested if immune-suppressing medications prove ineffective. Eculizumab and ravulizumab, monoclonal antibodies, are examples of these medications. However, their effectiveness varies.
Maintaining a diet that reduces sodium, potassium, and phosphorus, balances protein and healthy fat levels, and regulates fluid intake can help reduce strain on the kidneys. Some people with kidney conditions may work with a dietitian to create a personalized diet plan.
Recent research has uncovered new insights into the role of complement dysregulation in C3G, and an increasing number of complement inhibitors are being developed and tested. Iptacopan, an oral inhibitor of complement factor B, for example, has shown promise in reducing kidney C3 deposits and improving serum C3 levels in clinical trials.
The ongoing APPEAR-C3G clinical trial aims to evaluate new treatments for this ultra-rare kidney disease, reflecting efforts to develop effective therapies tailored to the underlying mechanism of C3G. Close monitoring of the condition is essential due to variable disease progression and the risk of progression to kidney failure.
References:1. Pregnancy outcome in C3 glomerulopathy2. ADVANCING THE TREATMENT OF ULTRA-RARE KIDNEY DISEASE C3 GLOMERULOPATHY3. Iptacopan in Complement-Driven Kidney Diseases4. Complement pathogenesis in C3 glomerulopathy5. C3 glomerulopathy: presentation, management, and current research
- Scientists are currently working on new therapies for the rare kidney disease, C3 Glomerulopathy (C3G), which has limited treatment options.
- The emerging therapies aim to interrupt the proteins involved in C3G, a condition that leads to protein buildup in the kidneys' filtering tissues.
- The immune system becomes overactive in C3G, due to changes in specific genes that regulate the body's complement system.
- Genetics are believed to play a role in the development of C3G, but it is not strictly inherited; most people with the condition carry antibodies that impair the regular function of the complement system.
- Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are used to manage C3G, helping lower blood pressure and limit protein leakage into the urine.
- MMF and glucocorticoids, both immune-suppressing drugs, may be recommended for people with declining kidney function or showing signs of condition progression.
- Complement inhibitors are also used to slow kidney damage caused by C3G, by stopping activity in the complement system.
- Eculizumab and ravulizumab are examples of complement inhibitor medications used for C3G, although their effectiveness varies.
- Maintaining a diet that reduces sodium, potassium, and phosphorus, balances protein and healthy fat levels, and regulates fluid intake can help reduce strain on the kidneys in those with C3G.
- Recent research has uncovered new insights into the role of complement dysregulation in C3G, resulting in the development of a growing number of complement inhibitors.
- Iptacopan, an oral inhibitor of complement factor B, has shown promise in reducing kidney C3 deposits and improving serum C3 levels in clinical trials.
- The APPEAR-C3G clinical trial aims to evaluate new treatments for this ultra-rare kidney disease, reflecting efforts to develop effective therapies tailored to the underlying mechanism of C3G.
- Close monitoring of C3G is essential due to variable disease progression and the risk of progression to kidney failure.
- Pregnancy outcome in C3G has been studied, as it can pose challenges for women's health during childbirth.
- Efforts are being made to advance the treatment of ultra-rare kidney diseases such as C3G, with Pfizer leading research on Iptacopan for complement-driven kidney diseases.
){kind=link}